Denali Therapeutics Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After Announcing on Thursday It Began Its Phase 2a Study of LRRK2 Inhibitor BIIB122 for LRRK2-associated Parkinson's Disease With Its First Participant Dosed.
Denali Therapeutics Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After Announcing on Thursday It Began Its Phase 2a Study of LRRK2 Inhibitor BIIB122 for LRRK2-associated Parkinson's Disease With Its First Participant Dosed.
denali therapeutics股价上涨。这支股票可能因为周四宣布开始进行LRRK2抑制剂BIIB122的2a期研究，该研究针对与LRRK2相关的帕金森病，并已对第一位参与者进行了剂量。
Denali Therapeutics Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After Announcing on Thursday It Began Its Phase 2a Study of LRRK2 Inhibitor BIIB122 for LRRK2-associated Parkinson's Disease With Its First Participant Dosed.
denali therapeutics股价上涨。这支股票可能因为周四宣布开始进行LRRK2抑制剂BIIB122的2a期研究，该研究针对与LRRK2相关的帕金森病，并已对第一位参与者进行了剂量。
资讯热榜
更新时间